Connect with us
We’re experimenting with AI-generated content to help deliver information faster and more efficiently.
While we try to keep things accurate, this content is part of an ongoing experiment and may not always be reliable.
Please double-check important details — we’re not responsible for how the information is used.

Chronic Illness

A New Target for Lyme Disease Treatment: Researchers Discover Achilles Heel of Borrelia Burgdorferi

Researchers have discovered that an enzyme can serve as an ideal target for developing new therapeutics against Lyme disease, and most likely other tick-borne diseases as well.

Avatar photo

Published

on

The discovery of a specific enzyme that can serve as an ideal target for developing therapeutics against Lyme disease has been reported in a recent study published in mBio, a journal of the American Society for Microbiology. This breakthrough could potentially lead to novel treatments and prevention methods for the most commonly reported tick-borne illness in the United States and Europe.

Lyme disease is caused by the bacterium Borrelia burgdorferi, which has evolved unique metabolic pathways that make it challenging to treat. Researchers at Virginia Commonwealth University had previously found that B. burgdorferi does not use thiamin as a cofactor, instead relying on lactate dehydrogenase (BbLDH) to convert pyruvate to lactate and balance the NADH/NAD+ ratio.

In their latest study, the researchers sought to establish the role of BbLDH in the pathophysiology of B. burgdorferi and explore its potential as a new therapeutic target. Using genetics, biochemistry, and X-ray crystallography, they elucidated the biochemical and structural features of BbLDH.

Loss-of-function studies revealed that BbLDH is essential for B. burgdorferi growth and infectivity in both in vitro and in vivo settings. Furthermore, high-throughput screening discovered several new LDH inhibitors.

This finding has significant implications for the development of novel therapeutics against Lyme disease. As corresponding study author Chunhao (Chris) Li noted, “BbLDH can serve as an ideal target for developing genus-specific inhibitors that can be potentially used to treat and prevent Lyme disease.”

The impact of Lyme disease on public health fuels an emerging demand for novel therapeutics to treat the illness. This report also sheds new light into understanding the role of LDH in the pathophysiology of other tick-borne pathogens, highlighting the potential for developing treatments that target multiple diseases simultaneously.

Overall, this breakthrough has the potential to revolutionize the treatment and prevention of Lyme disease, offering a promising new approach for combatting this debilitating illness.

Chronic Illness

The Surprising Link Between Hearing Loss, Loneliness, and Lifespan

People who treat hearing loss with hearing aids or cochlear implants regain rich conversations, escape isolation, and may even protect their brains and lifespans—proof that better hearing translates into fuller living.

Avatar photo

Published

on

A groundbreaking new study has shed light on the surprising link between hearing loss, loneliness, and lifespan. Researchers from the USC Caruso Department of Otolaryngology – Head and Neck Surgery found that adults with hearing loss who used hearing aids or cochlear implants were more socially engaged and felt less isolated compared to those who didn’t use them.

The study, published in JAMA Otolaryngology – Head & Neck Surgery, is the first to link hearing aids and cochlear implants to improved social lives among adults with hearing loss. The researchers conducted a comprehensive review of 65 previously published studies, encompassing over five thousand participants, on how hearing aids and cochlear implants affect three key measures: social quality of life, perceived social handicap, and loneliness.

The findings suggest that hearing devices can help prevent the social disconnection and broader health consequences that can follow untreated hearing loss. When left unaddressed, hearing loss can make communication difficult, leading people to withdraw from conversations and social activities. This can lead to mental stimulation reduction, increased risk of loneliness, anxiety, depression, cognitive decline, and dementia.

The researchers found that adults using hearing devices feel more socially connected and less limited in social situations. They are better able to engage in group conversations and feel more at ease in noisy or challenging listening environments. Participants also reported feeling less socially handicapped by their hearing loss, with fewer barriers and frustrations during interactions and an improved ability to stay engaged without feeling excluded.

Those with cochlear implants reported the most improvement in their social quality of life, likely because cochlear implants offer greater hearing restoration than hearing aids, especially for individuals with more severe hearing loss. As a result, they may experience more noticeable improvements in social engagement once their hearing is restored.

While it was outside the scope of the study to measure how better social lives relate to improved cognitive outcomes, the researchers believe there may be a connection. Previous research has found managing hearing loss may be key to reducing the risk of cognitive decline and dementia. The study’s lead researcher, Janet Choi, MD, MPH, an otolaryngologist with Keck Medicine, believes that by restoring clearer communication, hearing devices may help preserve cognitive health by keeping the brain more actively involved and people more connected.

This research follows a January 2024 study by Choi showing that adults with hearing loss who use hearing aids have an almost 25% lower risk of mortality, suggesting that treating hearing loss can improve lifespan as well as social quality of life. These findings add to a growing body of research showing that hearing health is deeply connected to overall well-being.

Continue Reading

Alternative Medicine

Catching Parkinson’s Sooner: Tiny Twitches, Big Breakthroughs

These findings highlight the significance of rearing behavior and behavioral lateralization as potential behavioral markers for tracking the progression of Parkinson's disease.

Avatar photo

Published

on

The study of Parkinson’s disease (PD) has long focused on understanding its symptoms and how they impact patients. However, a new discovery has shed light on a critical aspect of the disease: the subtle behaviors that can indicate its progression. Researchers from the Shenzhen Institutes of Advanced Technology have made a groundbreaking find that could revolutionize how we diagnose and treat PD.

Midbrain dopamine neurons play a vital role in regulating movement, emotion, and reward processing. Dysfunction in these neurons is directly linked to PD. However, previous research has primarily concentrated on their functions in mood regulation and reward mechanisms. The new study aims to close this knowledge gap by investigating the role of dopamine neurons in more subtle and spontaneous behaviors.

The researchers employed a machine learning-enhanced three-dimensional analysis system to examine detailed motor behaviors in two mouse models of dopamine neuron depletion: an MPTP-induced PD model and an AAV-mediated DA neuron loss model. This innovative approach enabled them to capture nuanced behavioral features that traditional methods might overlook.

One significant finding was the association between subtle behaviors such as rearing, walking, and hunching with the loss of substantia nigra pars compacta (SNc) dopamine neurons. These behaviors were not correlated with the ventral tegmental area (VTA) dopamine neurons. The results suggest that these behaviors can serve as key behavioral biomarkers for SNc DA neuron loss.

Moreover, researchers observed notable behavioral lateralization in PD mice and confirmed that climbing behavior was also strongly correlated with the loss of DA neurons in the SNc. These findings highlight the significance of rearing behavior and behavioral lateralization as potential markers for tracking PD progression.

The study’s lead researcher, Prof. Xuemei Liu, emphasized the importance of connecting behavioral changes to targeted neural damage in understanding PD progression and improving treatment strategies. This groundbreaking discovery opens doors to new research avenues and may ultimately aid in developing more effective treatments for Parkinson’s disease patients.

Continue Reading

Allergy

The Resilient Enemy: Why Asthma Symptoms Persist Despite Powerful Drugs

Biological drugs have been a game-changer for people with severe asthma, helping them breathe easier and live more comfortably. But researchers at Karolinska Institutet have uncovered a surprising twist: while these treatments ease symptoms, they may not fully eliminate the immune cells that drive inflammation. In fact, some of these cells actually increase during treatment, suggesting the medication is managing symptoms without targeting the root cause. This could explain why asthma often returns when the drugs are stopped, raising questions about how long-term these treatments should be and whether we’re truly solving the underlying problem.

Avatar photo

Published

on

Asthma has long been a formidable foe for many people, causing symptoms that can range from mild discomfort to life-threatening attacks. While powerful biological drugs have significantly improved the lives of those with severe asthma, a recent study has shed light on why these symptoms often return despite treatment.

Biological drugs, or biologics, have become a crucial tool in managing severe asthma by helping patients keep their symptoms under control. However, researchers at Karolinska Institutet in Sweden discovered that certain immune cells, which play a significant role in asthma inflammation, do not disappear during treatment as previously thought. Instead, these inflammatory cells increase in number.

This finding suggests that biologics might not address the root cause of asthma, but rather manage its symptoms. As such, continued treatment may be necessary to keep the disease under control. This is particularly concerning considering that little is still known about the long-term effects of biologics like mepolizumab and dupilumab, which have been prescribed to asthmatics for less than ten years.

The study analyzed blood samples from 40 patients before and during treatment, using advanced methods such as flow cytometry and single-cell sequencing. Researchers were surprised to find that the levels of inflammatory cells in these patients increased rather than decreased. This could explain why inflammation of the airways often returns when the treatment is tapered or discontinued.

It is essential for researchers and medical professionals to understand the long-term immunological effects of biologics, as this knowledge can lead to more effective treatments and better outcomes for patients with severe asthma. The next stage of the study will involve analyzing samples from patients with a long treatment history and studying lung tissue to see how immune cells are affected in the airways.

The findings of this study have significant implications for the management and treatment of asthma, highlighting the need for continued research into the effects of biologics on the immune system.

Continue Reading

Trending